NLRP12 Deficiency Enhances Tofacitinib Efficacy in DSS Colitis Via STAT1-M1 Polarization
Inflammation · 2026
DOI: 10.1007/s10753-026-02461-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Inflammation, 2026. Verfasst von Yun Yi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China. Hauptthemen laut MEDLINE: Pyrimidines, Piperidines, STAT1 Transcription Factor, Colitis. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Tofacitinib, an oral pan-Janus kinase (JAK) inhibitor, induces rapid remission in ulcerative colitis (UC), but only ~60% of patients respond, highlighting the need for biomarkers to guide therapy. NLRP12, a NOD-like receptor, negatively regulates inflammation by restraining NF-κB signaling and modulating microbiota-host interactions. We hypothesized that NLRP12 deficiency skews macrophage polarization toward an M1-biased state dependent on JAK-STAT signaling, thereby enhancing responsiveness to JAK inhibition. Acute colitis was induced by Dextran Sodium Sulfate (DSS) in wild-type and Nlrp12⁻/⁻ mice. Disease severity was assessed by body weight, disease activity index, colon length, and histopathology. Tofacitinib (10 mg/kg) was administered orally from day 3 to 7. Macrophage infiltration and polarization (CD86⁺ M1, CD206⁺ M2) were assessed by flow cytometry, and STAT1 activation was measured in colon tissue and lipopolysaccharide (LPS)-stimulated bone marrow-derived macrophages (BMDMs) by Western blot. Nlrp12⁻/⁻ mice exhibited more severe DSS colitis, with elevated p-STAT1 levels, enhanced CD86⁺ M1 polarization, and reduced CD206⁺ M2 populations. Tofacitinib markedly ameliorated colitis in both genotypes but conferred greater benefit in Nlrp12⁻/⁻ mice, restoring weight, reducing histological damage, and selectively suppressing CD86⁺ M1 macrophages. In vitro, tofacitinib partially reversed the heightened STAT1 phosphorylation and M1 polarization in Nlrp12⁻/⁻ BMDMs. NLRP12 deficiency enhances macrophage JAK-STAT1 activation, increasing sensitivity to tofacitinib due to a proinflammatory M1-dominant state. This suggests that a high M1/M2 ratio and elevated p-STAT1 could guide JAK inhibitor therapy in UC, though their predictive value requires human validation. Targeting NLRP12 or macrophage polarization may optimize treatment outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China.
- Hubei Clinical Center and Key Laboratory of Intestinal and Colorectal Diseases, Wuhan, China.
- Department of Gastroenterology, Huadong Hospital Affiliated to Fudan University, Shanghai, China.
- Shanghai Key Laboratory of Clinical Geriatric Medicine, Shanghai, China.
- Department of Gastroenterology, The Sixth Hospital of Wuhan, Wuhan, China.
- Department of Gastroenterology, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China. qiuzhao@whu.edu.cn.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Yi, Y., Wei, Q., Chen, S., Li, L., Dekyi, W., Jia, H., Shu, X., Zhao, Q., & Chang, Y. (2026). NLRP12 Deficiency Enhances Tofacitinib Efficacy in DSS Colitis Via STAT1-M1 Polarization. Inflammation. https://doi.org/10.1007/s10753-026-02461-2
Vancouver
Yi Y, Wei Q, Chen S, Li L, Dekyi W, Jia H, et al. NLRP12 Deficiency Enhances Tofacitinib Efficacy in DSS Colitis Via STAT1-M1 Polarization. Inflammation. 2026. doi:10.1007/s10753-026-02461-2
BibTeX
@article{Yi2026,
author = {Yi, Yun and Wei, Qiaofang and Chen, Siyu and Li, Lurao and Dekyi, Wangdron and Jia, Hangqi and Shu, Xiawen and Zhao, Qiu and Chang, Ying},
title = {NLRP12 Deficiency Enhances Tofacitinib Efficacy in DSS Colitis Via STAT1-M1 Polarization},
journal = {Inflammation},
year = {2026},
doi = {10.1007/s10753-026-02461-2}
}
EUVIMED